A Novel Stratum-Specific Trial Design Improves Statistical Power for Rare Diseases with Heterogenous Clinical Symptoms September 22, 2026

https://www.fda.gov/drugs/regulatory-science-action/impact-stories?utm_medium=email&utm_source=govdelivery A Novel Stratum-Specific Trial Design Improves Statistical Power for Rare Diseases with Heterogeneous Clinical Symptoms Clinical trials for rare diseases face significant statistical challenges: small patient populations limit enrollment and the heterogeneous clinical presentations common to many rare diseases further reduce statistical power by making it difficult to identify a single primary endpoint applicable to all participants. Traditional trial designs either enroll all patients using uniform endpoints regardless of their symptoms or restrict enrollment to patients experiencing all symptoms under investigation — both approaches can substantially limit a trial's power. To address these challenges, CDER statisticians developed a novel stratum-specific trial design in which patients are grouped into subpopulations based on the symptoms they experience at baseline, and treatment efficacy is evaluated using only the endpoints relevant to each patient's subpopulation. Using computer simulations, researchers compared this design against traditional global test approaches and found substantial gains in statistical power for a given subpopulation size — meaning fewer total patients are needed to achieve the same level of evidence as a traditionally designed trial. When followed by the Hochberg method for multiple testing correction, the design also maintained reasonable power to draw conclusions about treatment effects on specific symptoms. The stratum-specific design has important limitations, including a weaker interpretation of significant global test results compared to traditional trials, and an assumption of well-defined, accurately categorized subpopulations at baseline that does not account for patient misclassification or post-randomization symptom changes. Despite these limitations, CDER researchers suggest this framework offers a valuable and flexible paradigm for rare disease drug development, with the potential to support more efficient clinical trials and strengthen the evidence base for regulatory approval of effective therapies. Sponsors are encouraged to explore this design further through FDA's Complex Innovative Trial Design Meeting Program and the LEADER 3D initiative. Advancing Regulatory Science https://www.fda.gov/science-research/science-and-research-special-topics/advancing-regulatory-science?utm_medium=email&utm_source=govdelivery